Home › Pancreatic Cancer › NCT07756281

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults (18 years and older).
* Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
* Cancer confirmed by tissue or cell examination (histology or cytology).
* At least one measurable tumor on scans.
* Good enough general health and organ function to receive study treatment, as judged by the study doctor.
* Able to swallow oral medicines.
* Willing to follow study visit schedule and contraception requirements.

Exclusion Criteria:

* Serious heart, lung, liver, or other medical problems that would make study treatment unsafe.
* Active, uncontrolled infections.
* Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated).
* Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions).
* Known brain or nervous system involvement from the cancer that is not stable or controlled.
* Pregnant or breastfeeding, or unwilling to use required birth control during and after the study.

About the study

This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.

What is being tested

• SNV1521 (drug)
• daraxonrasib (drug)

Sponsor: ParVation Therapeutics, Inc. · Participants: 40 · Started: Sep 1, 2026

Contact the study team

• Kevin O'Hayer · Phone: 919-451-6590

Official record on ClinicalTrials.gov — NCT07756281

Locations in the U.S.

Conditions

• Pancreatic Cancer

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.